logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir

Dr. Reddy's Laboratories Ltd. (RDY) announced that it has entered licensing deal with Gilead Sciences, Inc. (GILD) to register, manufacture and sell Gilead's antiviral drug Remdesivir for the treatment of COVID-19, in 127 countries including India.

Under non-exclusive licensing agreement, Dr. Reddy's will receive technology transfer from Gilead for manufacturing of Remdesivir. Dr. Reddy's would need to do manufacturing scale up and obtain regulatory approval for marketing of Remdesivir in respective countries.

In May, FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir to treat Covid-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
Follow RTT